Status:
UNKNOWN
Combination Therapy of Betaseron-Prograf in Multiple Sclerosis
Lead Sponsor:
Clinique de sclérose en plaques et neuromusculaire de l'Outaouais
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to evaluate the safety and tolerability of a combination of interferon beta 1-b (Betaseron®) and tacrolimus (Prograf®) in patients suffering from multiple sclerosis (MS) wh...
Eligibility Criteria
Inclusion
- relapsing-remitting or secondary-progressive multiple sclerosis
- patients who have failed treatment with approved immunomodulator drugs (having experienced same or higher annual relapse rate or having experinced progression on the EDSS scale)
- Expanded Disability Status Scale (EDSS) score less than 7.0
Exclusion
- any of the following conditions: diabetes mellitus, uncontrolled hypertension, active infection or viral diseases
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00298662
Start Date
February 1 2003
End Date
September 1 2006
Last Update
March 3 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique de sclérose en plaques et neuromusculaire
Gatineau, Quebec, Canada, J8Y 1W7